Nigel A J McMillan
Overview
Explore the profile of Nigel A J McMillan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin M, Maniam P, Li D, Tang B, Bishop C, Suhrbier A, et al.
Mol Ther Nucleic Acids
. 2025 Jan;
36(1):102424.
PMID: 39817192
Currently, no approved antiviral drugs target dengue virus (DENV) infection, leaving treatment reliant on supportive care. DENV vaccine efficacy varies depending on the vaccine type, the circulating serotype, and vaccine...
2.
Vora S, Chatterjee S, Andrew A, Kumar R, Proctor M, Zeng Z, et al.
Cell Death Dis
. 2025 Jan;
16(1):7.
PMID: 39779678
Polyploidy is a common outcome of chemotherapies, but there is conflicting evidence as to whether polyploidy is an adverse, benign or even favourable outcome. We show Aurora B kinase inhibitors...
3.
Shirmast P, Shahri M, Brent A, Idris A, McMillan N
Mol Ther Nucleic Acids
. 2024 Dec;
35(4):102373.
PMID: 39618821
RNA science has experienced a surge, particularly its application to vaccine and therapeutic development. Delivery of RNA molecules into the brain remains one of the biggest therapeutic challenges with the...
4.
Chokwassanasakulkit T, McMillan N
Rev Med Virol
. 2024 Sep;
34(5):e2580.
PMID: 39228116
Merkel cell polyomavirus (MCPyV) is a significant contributor to the development of Merkel cell carcinoma (MCC), an aggressive skin cancer with high recurrence and a low survival rate. In fact,...
5.
Oti V, Idris A, McMillan N
Expert Rev Anti Infect Ther
. 2024 Jul;
22(8):647-657.
PMID: 38973346
Introduction: Respiratory syncytial virus (RSV) causes bronchiolitis and other respiratory issues in immunocompromised individuals, the elderly, and children. After six decades of research, we have only recently seen the approval...
6.
Idris A, Shrivastava S, Supramaniam A, Ray R, Shevchenko G, Acharya D, et al.
Nucleic Acid Ther
. 2024 Mar;
34(3):101-108.
PMID: 38530082
Long antisense RNAs (asRNAs) have been observed to repress HIV and other virus expression in a manner that is refractory to viral evolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...
7.
Idris A, Supramaniam A, Tayyar Y, Kelly G, McMillan N, Morris K
Antiviral Res
. 2024 Jan;
222:105815.
PMID: 38246206
There remains a striking overall mortality burden of COVID-19 worldwide. Given the waning effectiveness of current SARS-CoV-2 antivirals due to the rapid emergence of new variants of concern (VOC), we...
8.
Khanam F, Babu G, Rahman N, Liu X, Rajib N, Ahmed S, et al.
Vaccine
. 2023 Apr;
41(19):3137-3140.
PMID: 37061369
A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE)...
9.
Supramaniam A, Tayyar Y, Clarke D, Kelly G, Acharya D, Morris K, et al.
J Microbiol Immunol Infect
. 2023 Mar;
56(3):516-525.
PMID: 36934064
RNA interference (RNAi) is an emerging and promising therapy for a wide range of respiratory viral infections. This highly specific suppression can be achieved by the introduction of short-interfering RNA...
10.
Chowdhury F, Aziz A, Ahmmed F, Ahmed T, Kang S, Im J, et al.
Vaccine
. 2023 Mar;
41(14):2368-2375.
PMID: 36898931
The current global initiative to end Cholera by 2030 emphasizes the use of oral cholera vaccine (OCV) combined with feasible household Water-Sanitation-Hygiene (WASH) interventions. However, little is known about how...